Form 4: Crinetics Pharmaceuticals' Chief Scientific Officer Sells Shares
SEC Form 4 Filing
Stephen F. Betz, Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on July 25, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Stephen F. Betz, the Chief Scientific Officer of Crinetics Pharmaceuticals, sold 3,000 shares of common stock on July 25, 2024.
- The sale was executed automatically under a Rule 10b5-1 trading plan.
- The shares were sold in open market transactions at a volume weighted average price of $53.43 per share.
- The price range for the sales on that day was $53.41 to $53.45.
- Following the transaction, Betz still beneficially owns 75,611 shares of Crinetics Pharmaceuticals' common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative prospects for the company.
Industry Context
Insider sales are common and can be for various reasons, including diversification or personal financial planning. The use of a 10b5-1 plan suggests the sale was pre-planned and not based on immediate inside information.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
Key Dates
| Date | Description |
|---|---|
| 07/25/2024 | Date of the stock sale transaction. |
| 07/26/2024 | Date of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.